Interestingly, this led to the suggestion that, since no targeted therapy has been developed to date for Marfan syndrome, the prevention or reversal of the SirT1 GS-ylated state may represent a new therapeutic strategy to prevent the dissection/rupture of the TAA in these subjects [55]. This evidence concerns the gene SIRT1 and Marfan syndrome.